*/
Drug misuse remains a recurrent feature in family proceedings, often shaping decisions around safeguarding, supervision and contact.
However, the substance abuse landscape is no longer confined to heroin, cocaine, and cannabis. Toxicology laboratories are seeing an increase in controlled prescription drug misuse, the continued emergence of New Psychoactive Substances (NPS), and a marked rise in poly-drug use.
In addition, street drugs are increasingly adulterated or contaminated, meaning individuals may be unaware of the full range of substances they have consumed, many of which fall outside standard drug testing panels and may not be detected unless specifically requested.
For legal practitioners, it is no longer enough to know whether someone has taken a drug. Understanding what that drug is, how it is classified, and how it is typically used is equally important.
In family cases, how a substance is classified under UK law can have a real bearing on how risk is assessed and how evidence is framed.
Importantly, legal status does not necessarily reflect safeguarding risk. A substance may be lawfully prescribed, yet misused in a manner that impairs cognition, behaviour, or parenting capacity.
While traditional illicit drugs remain relevant, family practitioners are increasingly encountering a broader spectrum of substances in legally-instructed testing:
We are also seeing increasing misuse of prescription-only medications including anticonvulsants like gabapentin and pregabalin, antidepressants, antipsychotics, and anabolic steroids. These substances may be lawfully prescribed, yet excessive or non-prescribed use can contribute to mood instability, cognitive impairment, or behavioural volatility.
Understanding the main drug groups can help shape the scope of testing instructed and avoid gaps in the evidential picture.
Standard drug panels are designed to detect the most misused controlled substances. However, where prescription drug misuse, synthetic cannabinoids, or emerging psychoactive substances are suspected, an extended panel may be required.
Results must also be interpreted within clinical and behavioural context. The presence of a prescribed medication does not automatically indicate misuse; conversely, lawful access does not negate safeguarding concerns.
In response to demand for our previous guide, Drug & Alcohol Testing: a summary of testing options, we have developed a complementary guide for family law professionals: The main drug groups in the UK: legislation, medical applications and symptoms of misuse.
The guide provides:
Marie Law is Director of Toxicology at AlphaBiolabs. A highly-skilled and respected scientist with over 15 years’ experience in the field of forensics, Marie joined AlphaBiolabs in 2022 and oversees the company’s growing toxicology team. As Director of Toxicology, Marie’s day-to-day responsibilities include maintaining the highest quality testing standards for toxicology and further enhancing AlphaBiolabs’ drug and alcohol testing services for the legal sector, members of the public, and the workplace sector.
Drug misuse remains a recurrent feature in family proceedings, often shaping decisions around safeguarding, supervision and contact.
However, the substance abuse landscape is no longer confined to heroin, cocaine, and cannabis. Toxicology laboratories are seeing an increase in controlled prescription drug misuse, the continued emergence of New Psychoactive Substances (NPS), and a marked rise in poly-drug use.
In addition, street drugs are increasingly adulterated or contaminated, meaning individuals may be unaware of the full range of substances they have consumed, many of which fall outside standard drug testing panels and may not be detected unless specifically requested.
For legal practitioners, it is no longer enough to know whether someone has taken a drug. Understanding what that drug is, how it is classified, and how it is typically used is equally important.
In family cases, how a substance is classified under UK law can have a real bearing on how risk is assessed and how evidence is framed.
Importantly, legal status does not necessarily reflect safeguarding risk. A substance may be lawfully prescribed, yet misused in a manner that impairs cognition, behaviour, or parenting capacity.
While traditional illicit drugs remain relevant, family practitioners are increasingly encountering a broader spectrum of substances in legally-instructed testing:
We are also seeing increasing misuse of prescription-only medications including anticonvulsants like gabapentin and pregabalin, antidepressants, antipsychotics, and anabolic steroids. These substances may be lawfully prescribed, yet excessive or non-prescribed use can contribute to mood instability, cognitive impairment, or behavioural volatility.
Understanding the main drug groups can help shape the scope of testing instructed and avoid gaps in the evidential picture.
Standard drug panels are designed to detect the most misused controlled substances. However, where prescription drug misuse, synthetic cannabinoids, or emerging psychoactive substances are suspected, an extended panel may be required.
Results must also be interpreted within clinical and behavioural context. The presence of a prescribed medication does not automatically indicate misuse; conversely, lawful access does not negate safeguarding concerns.
In response to demand for our previous guide, Drug & Alcohol Testing: a summary of testing options, we have developed a complementary guide for family law professionals: The main drug groups in the UK: legislation, medical applications and symptoms of misuse.
The guide provides:
Far-ranging month for the Chair of the Bar
Endometriosis Awareness North, a charity raising awareness of endometriosis and supporting those affected across the North of England, has received a £500 boost from AlphaBiolabs via the company’s Giving Back initiative
Marie Law, Director of Toxicology at AlphaBiolabs, examines the most recent data on alcohol misuse in the UK, and the implications for alcohol testing in family proceedings
Clement Cowley, Partner at The Penny Group, explains how tailored financial planning can help barristers take control of their finances and plan with confidence
Marie Law, Director of Toxicology at AlphaBiolabs
A £500 donation from AlphaBiolabs has been made to the leading UK charity tackling international parental child abduction and the movement of children across international borders
Heritage as an anchor and a compass, finding our common humanity and embracing the power of the outsider – Melina Antoniadis’s lessons learnt
Is the Judicial Conduct Investigations Office process fit for purpose? Women barristers’ experiences of bullying are not being reported or, if they are, they are not making it through the system, says Tana Adkin KC
Review by Daniel Barnett
Chair of the Bar reports back
The client’s best interests could be well-served by sharing the advocacy with junior counsel more often than you might think – Naomi Cunningham and Charlotte Eves explore some less orthodox ways to divide the speaking role
